-
Mashup Score: 44Cell therapy bigwigs endorse CAR-T in Nature Medicine article amid FDA safety probe - 4 month(s) ago
As an FDA investigation into patients developing secondary T-cell cancers
Source: www.fiercepharma.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Bitter rivals. Beloved friends. Survivors. - 4 month(s) ago
After decades as rivals and friends, tennis greats Chris Evert and Martina Navratilova found themselves more intertwined than ever as they battled cancer.
Source: www.washingtonpost.comCategories: General Medicine News, Hem/OncsTweet-
A beautifully written Christmas read. Two extraordinary women and their decades of friendship. The always wonderful Sally Jenkins outdoes herself. https://t.co/J7tZHhuzff
-
-
Mashup Score: 0Bitter rivals. Beloved friends. Survivors. - 4 month(s) ago
After decades as rivals and friends, tennis greats Chris Evert and Martina Navratilova found themselves more intertwined than ever as they battled cancer.
Source: www.washingtonpost.comCategories: General Medicine News, Hem/OncsTweet-
A beautifully written Christmas read. Two extraordinary women and their decades of friendship. The always wonderful Sally Jenkins outdoes herself. https://t.co/J7tZHhuzff
-
-
Mashup Score: 103FDA opens review of CAR-T safety after identifying 19 cases of post-treatment blood cancer - 5 month(s) ago
The FDA is reviewing the safety of CAR-T therapies after reports of patients who developed blood cancers following treatment with the products, an inquiry that’s almost certain to raise questions about the class as its developers seek to expand its use. The agency told Endpoints News that it has received
Source: endpts.comCategories: General Medicine News, Hem/OncsTweet-
This came out of the blue and seems on initial reading to be overblown. FDA opens review of CAR-T safety after identifying 19 cases of post-treatment blood cancer - https://t.co/hG6glFLgZP
-
-
Mashup Score: 103FDA opens review of CAR-T safety after identifying 19 cases of post-treatment blood cancer - 5 month(s) ago
The FDA is reviewing the safety of CAR-T therapies after reports of patients who developed blood cancers following treatment with the products, an inquiry that’s almost certain to raise questions about the class as its developers seek to expand its use. The agency told Endpoints News that it has received
Source: endpts.comCategories: General Medicine News, Hem/OncsTweet-
This came out of the blue and seems on initial reading to be overblown. FDA opens review of CAR-T safety after identifying 19 cases of post-treatment blood cancer - https://t.co/hG6glFLgZP
-
-
Mashup Score: 4Nobel Prize in medicine awarded to scientists who laid foundation for messenger RNA vaccines - 7 month(s) ago
The Nobel Prize in medicine was awarded to Katalin Kariko and Drew Weissman, scientists who worked together to turn messenger RNA from a fragile genetic material that triggered a problematic immune response into a powerful medicine. Their key breakthrough in 2005 went largely unnoticed, but is now the backbone of two leading coronavirus vaccines and could lead to a whole new class of vaccines and drugs.
Source: www.washingtonpost.comCategories: Latest Headlines, Oncologists1Tweet-
Fantastic news Nobel Prize in medicine awarded to scientists who laid foundation for messenger RNA vaccines https://t.co/0vhOJUpshT
-
-
Mashup Score: 2(1) Post | Feed | LinkedIn - 8 month(s) ago
Feed post Mark Flower • 3rd+ VP Business Development | Cell Therapy Enthusiast 1h • Edited • …
Source: www.linkedin.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Great opening panel at #CARTCR, thanks to Adrian Bot for leading the discussion. @NovartisScience @KitePharma @CHOPCancerCntr https://t.co/NTPFWkjb0U
-
-
Mashup Score: 0
– First CRISPR gene-editing filings to be accepted for review by FDA – – FDA grants Priority Review for severe sickle cell disease (SCD) and Standard Review for transfusion-dependent beta thalassemia (TDT) – – PDUFA target action date of December 8, 2023 , for SCD and March 30, 2024 , for TDT –
Source: CRISPR TherapeuticsCategories: Hem/Oncs, Latest HeadlinesTweet-
Very excited to see info on the FDA acceptance of BLAs for #sicklecell disease and thalassemia with @VertexPharma exa-cel product. First CRISPR-engineered cell therapy product, hopefully the first of many. Looking forward to updated data at #EHA2023 https://t.co/czUijbe2rM
-
-
Mashup Score: 0
Sinusoidal obstruction syndrome, also known as veno-occlusive disease, is a potentially life-threatening complication of haematopoietic stem-cell tran…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Just out in @TheLancetHaem Defibritode RCT for #VOD prevention in #HSCT - no difference in VOD-free survival between DF and best supportive care - no safety signal in this RCT - bleeding similar between arms https://t.co/2lcND2uywG
-
-
Mashup Score: 2Is $3.5 Million a Fair Price for a Lifesaving Gene Therapy? - 1 year(s) ago
Here’s why gene therapies are the most expensive drugs in the world —and how these groundbreaking treatments could severely strain our health care system.
Source: WebMDCategories: Hem/Oncs, Latest HeadlinesTweet-
Price and value and access all coming together. Is $3.5 Million a Fair Price for a Lifesaving Gene Therapy? https://t.co/UZ4Fb1Lwq6 from @WebMD;
-
Could the FDA's warnings about T cell lymphoma after #CART have benefited from some context? Or additional detail? What does "life-long monitoring" mean in practical terms? Cell therapy bigwigs endorse CAR-T in Nature Medicine article https://t.co/Bw4AY7QCid